Bankruptcy Surge in the US Biotech and Pharmaceutical Companies in 2023 Sets a 10-Year Record

The year 2023 witnessed a staggering increase in bankruptcies among biotechnology and pharmaceutical companies in the United States, with the situation being described as "widespread devastation." The brief emergence and subsequent demise of small and medium-sized enterprises underscored the challenges faced by companies in post-pandemic times in terms of financing and economic recovery.

According to filings with the Securities and Exchange Commission (SEC), as of October 11, a record-breaking 28 biotech and pharmaceutical companies in the US had filed for bankruptcy in 2023, marking a 10-year high.

Financial analysts at Cassel Salpeter & Co. predict that more bankruptcies will occur by the end of the year. In 2022, there were 20 bankruptcy cases among biotech companies, compared to only 9 in 2021.

Reasons for the Surge in Biotech and Pharmaceutical Company Bankruptcies in 2023:

1. Inability to Keep Pace with Rapid Industry Advancements:
The rapid pace of advancements in biotechnology and pharmaceuticals has contributed to the downfall of several companies unable to keep up with industry trends. The sheer number of companies in the biotech sector and intense competition necessitate attracting investment on the capital market for survival. To secure investments, companies must develop technologies that effectively address real-world problems, as investors increasingly prioritize data, particularly clinical data.

2. High Investment Requirements and Project Failures:
The pharmaceutical sector, in particular, requires substantial investment in developing multiple projects to have a higher chance of regulatory approval. However, behind this considerable investment lies the risk of project failures and the inability to recoup investments, which can lead to bankruptcy. Nearly half of the bankrupt companies in the biotech sector faced survival crises due to failed clinical trials or terminated developments. For instance, SioGene Therapies, a company focused on treating rare neurodegenerative diseases, faced multiple setbacks since its inception and went through several name changes.

3. Financial Challenges and Inflation:
The volatility of financial markets plays a crucial role in the survival of biotech and pharmaceutical companies. Rising interest rates make it more difficult for biotech companies to raise funds, resulting in more companies filing for bankruptcy due to a lack of liquidity and accessible capital, leading to asset sales.

4. Impact of COVID-19 Pandemic:
The root cause of many biotech company bankruptcies lies in the disruption of cash flow and depleted funds. The COVID-19 outbreak caused clinical research to stall, requiring substantial funds to restart operations. Companies that fail to secure the necessary funding may face the imminent threat of bankruptcy. Layoffs often serve as an early indicator of financial depletion. Although the pandemic has subsided, the stagnant state of clinical and technological development requires significant funding to rejuvenate. Failure to raise adequate capital forces some companies to face the reality of bankruptcy.

The surge in bankruptcies among US biotech and pharmaceutical companies in 2023 can be attributed to various factors, including the inability to keep pace with industry advancements, high investment requirements, financial challenges, and the lingering impact of the COVID-19 pandemic. While bankruptcy protection allows companies to continue operations and formulate restructuring plans, the ability to secure funding, improve operations, reduce costs, increase sales, and explore new financing sources becomes crucial for successful reemergence. The application of artificial intelligence technologies in drug development holds potential for reducing the lengthy drug discovery process and lowering investment requirements, providing favorable conditions for the financial turnover and project management of small and medium-sized biotech companies. Consequently, the trends observed in 2023 may experience a reversal in the coming years.